Ian C. Mortimer
President, CEO & DirectorMr. Ian C. Mortimer, M.B.A, C.P.A, C.M.A., has been the Chief Executive Officer and Director at Xenon Pharmaceuticals Inc. since June 03, 2021 and was its Interim CFO & Principal Financial Officer since June 30, 2025. Mr. Mortimer was the Executive Vice President and Chief Financial Officer at Tekmira Pharmaceuticals Corporation. He had been an Independent Director at Perimeter Medical Imaging AI, Inc. since July 3, 2020 until December 29, 2025. He had been Chairman of Appili Therapeutics Inc. since January 2020 until November 2022 and served as its Director since November 2017 until November 2022. Mr. Mortimer serves as President of Xenon Pharmaceuticals Inc. since March 2018 and served as its Corporate Secretary since June 2015 until March 2021. He had been the Chief Financial Officer of Xenon Pharmaceuticals Inc. since October 2013 until March 2015 and served as its Chief Operating Officer since March 12, 2015 until June 2015. Mr. Mortimer has an extensive experience in the biotechnology sector. He served as the Chief Financial Officer of Arbutus Biopharma Corporation from December 17, 2004 to October 7, 2013 and served as its Executive Vice President of Finance from May 2008 to October 7, 2013. He was responsible for all aspects of Arbutus Biopharma Corporation?s finance and capital markets activities. He is accredited with leading both Xenon?s and Arbutus Biopharma Corporation?s listings on the NASDAQ, in 2014 and 2010 respectively. He served as Director of Investor Relations at Marret Resource Corp. He joined Marret Resource Corp. (alternate name Primary Corp.) in 1997. He served as Chief Financial Officer and Executive Vice President of Finance at Protiva Biotherapeutics, Inc. He served as an Executive Vice President at Arbutus Biopharma Corporation and Senior Vice President of Finance since December 17, 2004. Prior to his most recent position at Arbutus Biopharma Corporation, he served as Chief Financial Officer at Inex Pharmaceuticals Corporation since 2004 until 2007. He served as the Chief Financial Officer and Vice President of Finance of Primary Corp. since December 17, 2004. He served as Director of Investor Relations at Primary Corp. In 2004, he was recognized as Best Investor Relations Officer for a Small Cap Company in Canada. He served as Director of Primary Corp. and Marret Resource Corp. since April 30, 2007. He is a Chartered Professional Accountant and Certified Management Accountant. He has a B.Sc. in Microbiology from the University of British Columbia and an M.B.A. from Queen?s University.
Positions
- Company NameXenon Pharmaceuticals Inc.Stock CodeXENEPositionPresident, CEO & DirectorColleagues
- DADawn A. SvoronosIndependent Chairman
- TPThomas Patrick KellyChief Financial Officer
- ADAndrea DiFabioChief Legal Officer & Corporate Secretary
- CJChristopher John KenneyChief Medical Officer
- DSDarren S. ClineChief Commercial Officer
- SRSteven R. GannonIndependent Director
- JDJustin D. GoverIndependent Director
- GPGary PatouIndependent Director
